Positron emission tomography (PET) and magnetic resonance imaging (MRI) for the assessment of axillary lymph node metastases in early breast cancer: Systematic review and economic evaluation

Health Technology Assessment

Volumn 15, Issue 4, 2011, Pages

  Cooper, K L ^a   Meng, Y ^a   Harnan, S ^a   Ward, S E ^a   Fitzgerald, P ^a   Papaioannou, D ^a   Wyld, L ^b   Ingram, C ^b   Wilkinson, I D ^b   Lorenz, E ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; GADOLINIUM; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; AXILLARY LYMPH NODE; BIBLIOGRAPHIC DATABASE; BREAST CANCER; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CINAHL; CLINICAL EXAMINATION; COMPARATIVE EFFECTIVENESS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DATA ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG ERUPTION; EARLY CANCER; ECHOGRAPHY; ECONOMIC EVALUATION; EMBASE; FALSE NEGATIVE RESULT; HEALTH CARE COST; HUMAN; INTERMETHOD COMPARISON; INTRAOPERATIVE PERIOD; LOW BACK PAIN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHEDEMA; MEDICAL DECISION MAKING; MEDLINE; META ANALYSIS; MICROMETASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; ORTHOSTATIC INTOLERANCE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PROTON NUCLEAR MAGNETIC RESONANCE; PRURITUS; QUALITY ADJUSTED LIFE YEAR; QUALITY CONTROL; RECURRENCE RISK; REVIEW; RISK BENEFIT ANALYSIS; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY; SYSTEMATIC REVIEW; THORAX PAIN; TREATMENT CONTRAINDICATION; UNITED KINGDOM;

EID: 79951572712     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta15040     Document Type: Review

References (232)

1. Office for National Statistics. Cancer registration statistics England 2007: MB1 No 38. URL: www.statistics.gov.uk/StatBase/Product.asp?vlnk=7720&Pos=1&ColRank=1&Rank=272 (accessed 29 November 2010).
2. Welsh Cancer Intelligence & Surveillance Unit (WCISU). Cancer incidence in Wales 2003-2007. URL: www.wales.nhs.uk/sites3/Documents/242/Cancer%20Incidence%20in%20Wales%202003-2007.pdf (accessed 23 January 2009).
3. Dumitrescu RG, Cotarla I. Understanding breast cancer risk - where do we stand in 2005? J Cell Mol Med 2005;9(1):208-21.
4. Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58 209 women with breast cancer and 101 986 women without the disease. Lancet 2001;358(9291):1389-99.
5. Ziegler RG, Hoover RN, Pike MC, Hildesheim A, Nomura AM, West DW, et al. Migration patterns and breast cancer risk in Asian-American women. J Natl Cancer Inst 1993;85(22):1819-27.
6. Kahlenborn C, Modugno F, Potter DM, Severs WB. Oral contraceptive use as a risk factor for premenopausal breast cancer: a meta-analysis. Mayo Clin Proc 2006;81(10):1290-302.
7. Beral V. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52, 705 women with breast cancer and 108, 411 women without breast cancer. Lancet 1997;350(9084):1047-59.
8. Megdal SP, Kroenke CH, Laden F, Pukkala E, Schernhammer ES. Night work and breast cancer risk: a systematic review and meta-analysis. Eur J Cancer 2005;41(13):2023-32.
9. Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health 2009;9:88.
10. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008;371(9612):569-78.
11. Loi S, Milne RL, Friedlander ML, McCredie MRE, Giles GG, Hopper JL, et al. Obesity and outcomes in premenopausal and postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 2005;14(7):1686-91.
12. Kerlikowske K, Walker R, Miglioretti DL, Desai A, Ballard-Barbash R, Buist DSM, et al. Obesity, mammography use and accuracy, and advanced breast cancer risk. J Natl Cancer Inst 2008;100(23):1724-33.
13. Lagerros YT, Hsieh SF, Hsieh CC. Physical activity in adolescence and young adulthood and breast cancer risk: a quantitative review. Eur J Cancer Prev 2004;13(1):5-12.
14. Monninkhof EM, Elias SG, Vlems FA, van der Tweel I, Schuit AJ, Voskuil DW, et al. Physical activity and breast cancer: a systematic review. Epidemiology 2007;18(1):137-57.
15. Cancer Research UK. Breast cancer in men. URL: www.cancerhelp.org.uk/help/default.asp?page=5075 (accessed 1 May 2009).
16. Fisher B, Bauer M, Wickerham DL, Redmond CK, Fisher ER, Cruz AB, et al. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer 1983;52(9):1551-7.
17. National Institute for Health and Clinical Excellence (NICE), National Collaborating Centre for Cancer. Early and locally advanced breast cancer: diagnosis and treatment. Cardiff: National Collaborating Centre for Cancer; 2009.
18. Office for National Statistics. Survival Rates in England, patients diagnosed 2001-2006 followed up to 2007. URL: www.statistics.gov.uk/StatBase/Product.asp?vlnk=14007. 2007.
19. West Midlands Cancer Intelligence Unit. 0-10 year relative survival for cases of breast cancer by stage diagnosed in the West Midlands 1985-1989 followed up to the end of 1999, as at January 2002. Birmingham: West Midlands Cancer Intelligence Unit; 2009.
20. Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 1992;22(3):207-19.
21. Adjuvant! Online. Adjuvant! Online. Decision making tools for health care professionals. URL: www.adjuvantonline.com/index.jsp (accessed 29 November 2010).
22. Cancer Research UK. Cancer statistics: breast cancer UK. URL: http://publications.cancerresearchuk.org/WebRoot/crukstoredb/CRUK_PDFs/CSBREA09.pdf (accessed 1 May 2009).
23. Cancer Research UK, National Cancer Intelligence Network. Cancer incidence and survival by major ethnic group, England, 2002-2006. URL: http://publications.cancerresearchuk.org/WebRoot/crukstoredb/CRUK_PDFs/CR-UKNCIN_ETHNIC.pdf (acessed 1 June 2009).
24. Parkin DM, Fernandez LM. Use of statistics to assess the global burden of breast cancer. Breast J 2006;12(Suppl. 1):S70-S80.
25. National Cancer Intelligence Network. Cancer incidence by deprivation England, 1995-2004. URL: www.ncin.org.uk/publications/reports/default.apsx.
26. Welsh Cancer Intelligence & Surveillance Unit. Cancer incidence, mortality and survival by deprivation in Wales. URL: www.wales.nhs.uk/sites3/Documents/242/Deprivation%20in%20Wales%201993-2007.pdf (accessed 1 July 2009).
27. Cancer Research UK. Cancer survival and deprivation statistics. URL: http://info.cancerresearchuk.org/cancerstats/survival/survivaldeprivation/ (accessed 4 April 2005).
28. Office for National Statistics. Death registrations in England and Wales, 2008, causes. URL: www.statistics.gov.uk/pdfdir/dthreg0809.pdf (accessed 26 August 2009).
29. South East England Public Health Observatory, Oxford University. Breast cancer in England 1996 to 2004. Mortality trends. URL: www.uhce.ox.ac.uk/epidembase/temp_epi/trends_mortality.php.
30. Blanks RG, Moss SM, McGahan CE, Quinn MJ, Babb PJ. Effect of NHS breast screening programme on mortality from breast cancer in England and Wales, 1990-8: comparison of observed with predicted mortality. BMJ 2000;321(7262):665-9.
31. Kobayashi S. What caused the decline in breast cancer mortality in the United Kingdom? Breast Cancer 2004;11(2):156-9.
32. NHS Cancer screening programme. Breast awareness. URL: www.cancerscreening.nhs.uk/breastscreen/breastawareness.html (accessed 29 November 2010).
33. NHS Cancer screening programme. Breast cancer screening. URL: www.cancerscreening.nhs.uk/breastscreen/index.html (accessed 29 November 2010).
34. International Union Against Cancer. TNM classification of malignant tumours. 5th edn. New York, NY: Wiley-Liss; 1997.
35. Singletary SE, Connolly JL. Breast cancer staging: working with the sixth edition of the AJCC Cancer Staging Manual. CA Cancer J Clin 2006;56(1):37-47.
36. Cancer Research UK. TNM breast cancer staging. URL: www.cancerhelp.org.uk/help/default.asp?page=3316 (accessed 29 November 2010).
37. Agency for Healthcare Research and Quality (AHRQ). Surgery choices for women with earlystage breast cancer. URL: www.ahrq.gov/consumer/brcanchoice.htm. (accessed 29 November 2010).
38. US National Cancer Institute (NCI). Surgery choices for women with early-stage breast cancer. URL: www.cancer.gov/cancertopics/breast-cancer-surgery-choices. 2009.
39. American Cancer Society. How is breast cancer staged? URL: www.cancer.org/docroot/CRI/content/CRI_2_4_3X_How_is_breast_cancer_staged_5.asp. (accessed 29 November 2010).
40. Cancer Research UK. Number stages of breast cancer. URL: www.cancerhelp.org.uk/help/default.asp?page=3315. (accessed 29 November 2010).
41. Kvistad KA, Rydland J, Smethurst HB, Lundgren S, Fjosne HE, Haraldseth O. Axillary lymph node metastases in breast cancer: preoperative detection with dynamic contrast-enhanced MRI. Eur Radiol 2000;10(9):1464-71.
42. Mumtaz H, Hall-Craggs MA, Davidson T, Walmsley K, Thurell W, Kissin MW, et al. Staging of symptomatic primary breast cancer with MR imaging. AJR 1997;169(2):417-24.
43. Smith IC, Welch AE, Chilcott F, Heys SD, Sharp P, Eremin O. Gamma emission imaging in the management of breast disorders. Eur J Surg Oncol 1998;24(4):320-9.
44. Wahl RL, Siegel BA, Coleman RE, Gatsonis CG, PET Study Group. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group. J Clin Oncol 2004;22(2):277-85.
45. Wallace IW, Champton HR. Axillary nodes in breast cancer. Lancet 1972;1(7744):217-18.
46. Fisher B, Wolmark N, Bauer M, Redmond C, Gebhardt M. The accuracy of clinical nodal staging and of limited axillary dissection as a determinant of histologic nodal status in carcinoma of the breast. Surg Gynecol Obstet 1981;152(6):765-72.
47. Alvarez S, Anorbe E, Alcorta P, Lopez F, Alonso I, Cortes J. Role of sonography in the diagnosis of axillary lymph node metastases in breast cancer: a systematic review. AJR Am J Roentgenol 2006;186(5):1342-8.
48. Blanchard DK, Donohue JH, Reynolds C, Grant CS. Relapse and morbidity in patients undergoing sentinel lymph node biopsy alone or with axillary dissection for breast cancer. Arch Surg 2003;138(5):482-7.
49. Crane-Okada R, Wascher RA, Elashoff D, Giuliano AE. Long-term morbidity of sentinel node biopsy versus complete axillary dissection for unilateral breast cancer. Ann Surg Oncol 2008;15(7):1996-2005.
50. McLaughlin SA, Wright MJ, Morris KT, Giron GL, Sampson MR, Brockway JP, et al. Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: objective measurements. J Clin Oncol 2008;26(32):5213-19.
51. Purushotham AD, Upponi S, Klevesath MB, Bobrow L, Millar K, Myles JP, et al. Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial. J Clin Oncol 2005;23(19):4312-21.
52. Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst 2006;98(9):599-609.
53. Liu CQ, Guo Y, Shi JY, Sheng Y. Late morbidity associated with a tumour-negative sentinel lymph node biopsy in primary breast cancer patients: a systematic review. Eur J Cancer 2009;45(9):1560-8.
54. Wilke LG, McCall LM, Posther KE, Whitworth PW, Reintgen DS, Leitch AM, et al. Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol 2006;13(4):491-500.
55. Department of Health. NHS Reference Costs 2003. London: Department of Health; 2004.
56. Department of Health. NHS Reference Costs 2008. London: Department of Health; 2009.
57. Mansfield L, Sosa I, Dionello R, Subramanian A, Devalia H, Mokbel K. Current management of the axilla in patients with clinically node-negative breast cancer: a nationwide survey of United Kingdom breast surgeons. Int Semin Surg Oncol 2007;4:4.
58. Facey K, Bradbury I, Laking G, Payne E. Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers. Health Technol Assess 2007;11(44).
59. Cherry SR. The 2006 Henry N. Wagner lecture: of mice and men (and positrons)--advances in PET imaging technology. J Nucl Med 2006;47(11):1735-45.
60. Messa C, Bettinardi V, Picchio M, Pelosi E, Landoni C, Gianolli L, et al. PET/CT in diagnostic oncology. Q J Nucl Med Mol Imaging 2004;48(2):66-75.
61. Radiology Info. URL: www.radiologyinfo.org/en/info.cfm?pg=abdominct. (accessed 29 November 2010).
62. Erguvan-Dogan B, Whitman GJ, Kushwaha AC, Phelps MJ, Dempsey PJ. BI-RADS-MRI: a primer. AJR Am J Roentgenol 2006;187(2):W152-W160.
63. Lehman CD, Schnall MD. Imaging in breast cancer: magnetic resonance imaging. Breast Cancer Res 2005;7(5):215-19.
64. Yeung DK, Yang WT, Tse GM. Breast cancer: in vivo proton MR spectroscopy in the characterization of histopathologic subtypes and preliminary observations in axillary node metastases. Radiology 2002;225(1):190-7.
65. Medicines and Healthcare products Regulatory Agency (MHRA). Safety guidelines for magnetic resonance imaging equipment in clinical use: device bulletin. URL: www.mhra.gov.uk/Publications/Safetyguidance/DeviceBulletins/CON2033018. (accessed 29 November 2010).
66. Jacklin PB, Barrington SF, Roxburgh JC, Jackson G, Sariklis D, West PA, et al. Costeffectiveness of preoperative positron emission tomography in ischemic heart disease. Ann Thorac Surg 2002;73(5):1403-9.
67. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151(4):264-9, W64.
68. PRISMA statement website. URL: www.prisma-statement.org. (accessed 29 November 2010).
69. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003;3:25.
70. Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol 2005;58(10):982-90.
71. Leeflang MM, bets-Ossenkopp YJ, Visser CE, Scholten RJ, Hooft L, Bijlmer HA, et al. Galactomannan detection for invasive aspergillosis in immunocompromized patients. Cochrane Database Syst Rev 2008;4:CD007394.
72. Review Manager (revman). Version 5.0. 2008. Copenhagen, The Nordic Cochrane Centre, The Cochrane Collaboration.
73. Chae BJ, Bae JS, Kang BJ, Kim SH, Jung SS, Song BJ. Positron emission tomographycomputed tomography in the detection of axillary lymph node metastasis in patients with early stage breast cancer. Jpn J Clin Oncol 2009;39(5):284-9.
74. Heusner TA, Kuemmel S, Hahn S, Koeninger A, Otterbach F, Hamami ME, et al. Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients. Eur J Nucl Med Mol Imaging 2009;36(10):1543-50.
75. Kim J, Lee J, Chang E, Kim S, Suh K, Sul J, et al. Selective sentinel node plus additional nonsentinel node biopsy based on an FDG-PET/CT scan in early breast cancer patients: single institutional experience. World J Surg 2009;33(5):943-9.
76. Taira N, Ohsumi S, Takabatake D, Hara F, Takashima S, Aogi K, et al. Determination of indication for sentinel lymph node biopsy in clinical node-negative breast cancer using preoperative 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging. Jpn J Clin Oncol 2009;39(1):16-21.
77. Fuster D, Duch J, Paredes P, Velasco M, Munoz M, Santamaria G, et al. Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/ computed tomography compared with conventional imaging procedures. J Clin Oncol 2008;26(29):4746-51.
78. Ueda S, Tsuda H, Asakawa H, Omata J, Fukatsu K, Kondo N, et al. Utility of 18F-fluorodeoxyglucose emission tomography/computed tomography fusion imaging (18F-FDG PET/ CT) in combination with ultrasonography for axillary staging in primary breast cancer. BMC Cancer 2008;8:165.
79. Veronesi U, De CC, Galimberti VE, Fernandez JR, Rotmensz N, Viale G, et al. A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases. Ann Oncol 2007;18(3):473-8.
80. Cermik TF, Mavi A, Basu S, Alavi A. Impact of FDG PET on the preoperative staging of newly diagnosed breast cancer. Eur J Nucl Med Mol Imaging 2008;35(3):475-83.
81. Gil-Rendo A, Zornoza G, Garcia-Velloso MJ, Regueira FM, Beorlegui C, Cervera M. Fluorodeoxyglucose positron emission tomography with sentinel lymph node biopsy for evaluation of axillary involvement in breast cancer. Br J Surg 2006;93(6):707-12.
82. Weir L, Worsley D, Bernstein V. The value of FDG positron emission tomography in the management of patients with breast cancer. Breast J 2005;11(3):204-9.
83. Agresti R, Crippa F, Gerali A, Maccauro M, Giovanazzi R, Bombardieri E, et al. Lymph node metastases detection by FDG-PET and sentinel node biopsy in breast cancer patients: comparison of these different approaches. EJC Supplements 2004;2(3):81, abstract 86.
84. Fehr MK, Hornung R, Varga Z, Burger D, Hess T, Haller U, et al. Axillary staging using positron emission tomography in breast cancer patients qualifying for sentinel lymph node biopsy. Breast J 2004;10(2):89-93.
85. Inoue T, Yutani K, Taguchi T, Tamaki Y, Shiba E, Noguchi S. Preoperative evaluation of prognosis in breast cancer patients by [(18)F]2-Deoxy-2-fluoro-d-glucose-positron emission tomography. J Cancer Res Clin Oncol 2004;130(5):273-8.
86. Lovrics PJ, Chen V, Coates G, Cornacchi SD, Goldsmith CH, Law C, et al. A prospective evaluation of positron emission tomography scanning, sentinel lymph node biopsy, and standard axillary dissection for axillary staging in patients with early stage breast cancer. Ann Surg Oncol 2004;11(9):846-53.
87. Barranger E, Grahek D, Antoine M, Montravers F, Talbot JN, Uzan S. Evaluation of fluorodeoxyglucose positron emission tomography in the detection of axillary lymph node metastases in patients with early-stage breast cancer. Ann Surg Oncol 2003;10(6):622-7.
88. Guller U, Nitzsche EU, Schirp U, Viehl CT, Torhorst J, Moch H, et al. Selective axillary surgery in breast cancer patients based on positron emission tomography with 18F-fluoro-2- deoxy-d-glucose: not yet! Breast Cancer Res Treat 2002;71(2):171-3.
89. Nakamoto Y, Chang AE, Zasadny KR, Wahl RL, Nakamoto Y, Chang AE, et al. Comparison of attenuation-corrected and non-corrected FDG-PET images for axillary nodal staging in newly diagnosed breast cancer. Mol Imaging Biol 2002;4(2):161-9.
90. Rieber A, Schirrmeister H, Gabelmann A, Nuessle K, Reske S, Kreienberg R, et al. Preoperative staging of invasive breast cancer with MR mammography and/or PET: boon or bunk? Br J Radiol 2002;75(898):789-98.
91. van der Hoeven JJ, Hoekstra OS, Comans EF, Pijpers R, Boom RP, van Geldere D, et al. Determinants of diagnostic performance of [F-18]fluorodeoxyglucose positron emission tomography for axillary staging in breast cancer. Ann Surg 2002;236(5):619-24.
92. Greco M, Crippa F, Agresti R, Seregni E, Gerali A, Giovanazzi R, et al. Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-d-glucose-positron emission tomography: clinical evaluation and alternative management. J Natl Cancer Inst 2001;93(8):630-5.
93. Noh DY, Yun IJ, Kim JS, Kang HS, Lee DS, Chung JK, et al. Diagnostic value of positron emission tomography for detecting breast cancer. World J Surg 1998;22(3):223-8.
94. Smith IC, Ogston KN, Whitford P, Smith FW, Sharp P, Norton M, et al. Staging of the axilla in breast cancer - accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-d-glucose. Ann Surg 1998;228(2):220-7.
95. Adler LP, Faulhaber PF, Schnur KC, Al-Kasi NL, Shenk RR. Axillary lymph node metastases: screening with [F-18]2-deoxy-2-fluoro-d-glucose (FDG) PET. Radiology 1997;203(2):323-7.
96. Avril N, Dose J, Janicke F, Ziegler S, Romer W, Weber W, et al. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-d-glucose. J Natl Cancer Inst 1996;88(17):1204-9.
97. Utech CI, Young CS, Winter PF. Prospective evaluation of fluorine-18 fluorodeoxyclucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry. Eur J Nucl Med 1996;23(12):1588-93.
98. Crippa F, Agresti R, Seregni E, Greco M, Pascali C, Bogni A, et al. Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer. J Nucl Med 1998;39(1):4-8.
99. Bombardieri E, Crippa F, Agresti R, Leutner M, Delledonne V, Greco M, et al. FDG-PET in the assessment of axillary metastases in breast cancer. Clinical application and economic implications. J Nucl Med 1998;39(5):1119.
100. Crippa F, Agresti R, Donne VD, Pascali C, Bogni A, Chiesa C, et al. The contribution of positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) in the preoperative detection of axillary metastases of breast cancer: the experience of the National Cancer Institute of Milan. Tumori 1997;83(2):542-3.
101. Adler LP, Schnur KC, Faulhaber PF, Shenk RR. High sensitivity interpretation PET of the axilla: screening test for axillary lymph node metastases in patients with breast cancer. Radiology 1996;201:551.
102. Kumar R, Zhuang H, Schnall M, Conant E, Damia S, Weinstein S, et al. FDG PET positive lymph nodes are highly predictive of metastasis in breast cancer. Nucl Med Commun 2006;27(3):231-6.
103. Zornoza G, Garcia-Velloso MJ, Sola J, Regueira FM, Pina L, Beorlegui C. F-18-FDG PET complemented with sentinel lymph node biopsy in the detection of axillary involvement in breast cancer. Eur J Surg Oncol 2004;30(1):15-19.
104. Agresti R, Crippa F, Gerali A, Maccauro M, Giovanazzi R, Guida V, et al. Lymph node metastases detection by FDG-PET and sentinel node biopsy in breast cancer patients: comparison of these different approaches. Eur J Cancer 2001;37(Suppl. 6):S184, abstract 670.
105. Lovrics PJ, Chen V, Coates G, Cornacchi SD, Goldsmith C, Law C, et al. A prospective comparison of positron emission tomography scanning, sentinel lymph node biopsy and axillary dissection in staging patients with early stage breast cancer. Breast Cancer Res Treat 2002;76(Suppl. 1):S129, abstract 514.
106. Yutani K, Shiba E, Kusuoka H, Tatsumi M, Uehara T, Taguchi T, et al. Comparison of FDGPET with MIBI-SPECT in the detection of breast cancer and axillary lymph node metastasis. J Comput Assist Tomogr 2000;24(2):274-80.
107. Yutani K, Tatsumi M, Shiba E, Kusuoka H, Nishimura T. Comparison of dual-head coincidence gamma camera FDG imaging with FDG PET in detection of breast cancer and axillary lymph node metastasis. J Nucl Med 1999;40(6):1003-8.
108. Kimura K, Tanigawa N, Matsuki M, Nohara T, Iwamoto M, Sumiyoshi K, et al. Highresolution MR lymphography using ultrasmall superparamagnetic iron oxide (USPIO) in the evaluation of axillary lymph nodes in patients with early stage breast cancer: preliminary results. Breast Cancer 2010;17(4)241-6.
109. Harada T, Tanigawa N, Matsuki M, Nohara T, Narabayashi I. Evaluation of lymph node metastases of breast cancer using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging. Eur J Radiol 2007;63(3):401-7.
110. Memarsadeghi M, Riedl CC, Kaneider A, Galid A, Rudas M, Matzek W, et al. Axillary lymph node metastases in patients with breast carcinomas: assessment with nonenhanced versus uspio-enhanced MR imaging. Radiology 2006;241(2):367-77.
111. Stadnik TW, Everaert H, Makkat S, Sacre R, Lamote J, Bourgain C. Breast imaging. Preoperative breast cancer staging: comparison of USPIO-enhanced MR imaging and 18F-fluorodeoxyglucose (FDC) positron emission tomography (PET) imaging for axillary lymph node staging - initial findings. Eur Radiol 2006;16(10):2153-60.
112. Michel SC, Keller TM, Frohlich JM, Fink D, Caduff R, Seifert B, et al. Preoperative breast cancer staging: MR imaging of the axilla with ultrasmall superparamagnetic iron oxide enhancement. Radiology 2002;225(2):527-36.
113. Murray AD, Staff RT, Redpath TW, Gilbert FJ, Ah-See AK, Brookes JA, et al. Dynamic contrast enhanced MRI of the axilla in women with breast cancer: comparison with pathology of excised nodes. Br J Radiol 2002;75(891):220-8.
114. Lind PG. Radioimmunoscintigraphy with Tc-99m labeled monoclonal antibody 170H.82 in suspected primary, recurrent, or metastatic breast cancer. Clin Nucl Med 1997;22(1):30-4.
115. Pichler BJ, Wehrl HF, Judenhofer MS. Latest advances in molecular imaging instrumentation. J Nucl Med 2008;49(Suppl. 2):5S-23S.
116. Bellin MF. Non-gadolinium-based contrast agents. In Thomsen HS, Webb JAW, editors. Contrast media: safety issues and ESUR guidelines. 2nd edn. Berlin: Springer-Verlag; 2009. pp. 205-12.
117. Bellin MF, Roy C, Kinkel K, Thoumas D, Zaim S, Vanel D, et al. Lymph node metastases: safety and effectiveness of MR imaging with ultrasmall superparamagnetic iron oxide particles--initial clinical experience. Radiology 1998;207(3):799-808.
118. Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003;348(25):2491-9.
119. Sloka JS, Hollett PD, Mathews M. Cost-effectiveness of positron emission tomography in breast cancer. Mol Imaging Biol 2005;7(5):351-60.
120. Pandharipande PV, Harisinghani MG, Ozanne EM, Specht MC, Hur C, Lee JM, et al. Staging MR lymphangiography of the axilla for early breast cancer: cost-effectiveness analysis. AJR Am J Roentgenol 2008;191(5):1308-19.
121. Law AM. Simulation modeling and analysis. 4th edn. New York, NY: McGraw Hill; 2007.
122. Sato T, Yamaguchi K, Morita Y, Noikura T, Sugihara K, Matsune S. Lymphoscintigraphy for interpretation of changes of cervical lymph node function in patients with oral malignant tumors: comparison of Tc-99m-Re and Tc-99m-HSA-D. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000;90(4):525-37.
123. Tanaka K, Yamamoto D, Kanematsu S, Okugawa H, Kamiyama Y. A four node axillary sampling trial on breast cancer patients. Breast 2006;15(2):203-9.
124. Sato K, Tamaki K, Takeuchi H, Tsuda H, Kosuda S, Kusano S, et al. Management of the axilla in breast cancer: a comparative study between sentinel lymph node biopsy and four-node sampling procedure. Jpn J Clin Oncol 2001;31(7):318-21.
125. Kim T, Giuliano AE, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer 2006;106(1):4-16.
126. Hind D, Ward S, De Nigris E, Simpson E, Carroll C, Wyld L. Hormonal therapies for early breast cancer: systematic review and economic evaluation. Health Technol Assess 2007;11(26).
127. Jeruss JS, Hunt KK, Xing Y, Krishnamurthy S, Meric-Bernstam F, Cantor SB, et al. Is intraoperative touch imprint cytology of sentinel lymph nodes in patients with breast cancer cost effective? Cancer 2006;107(10):2328-36.
128. Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst 2006;98(9):599-609.
129. Ward S, Simpson E, Davis S, Hind D, Rees A, Wilkinson A. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation. Health Technol Assess 2007;11(40).
130. Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care 2000;38(6):583-637.
131. Ara R, Brazier J. Populating an economic mode with health state utility values: moving towards better practice. Value Health 2010;13(5):S09-18.
132. Office for National Statistics. Interim Life Tables, United Kingdom, 1980-82 to 2005-07. London: Office for National Statistics; 2008.
133. Orr RK, Col NF, Kuntz KM. A cost-effectiveness analysis of axillary node dissection in postmenopausal women with estrogen receptor-positive breast cancer and clinically negative axillary nodes. Surgery 1999;126(3):568-76.
134. Kamby C, Sengelov L. Pattern of dissemination and survival following isolated locoregional recurrence of breast cancer. A prospective study with more than 10 years of follow up. Breast Cancer Res Treat 1997;45(2):181-92.
135. Mak SS, Mo KF, Suen JJ, Chan SL, Ma WL, Yeo W. Lymphedema and quality of life in Chinese women after treatment for breast cancer. Eur J Oncol Nurs 2009;13(2):110-15.
136. Her Majesty's Treasury. The green book: appraisal and evaluation in central government. London: Her Majesty's Treasury; 2003.
137. Escalona S, Blasco JA, Reza MM, Andradas E, Gomez N. A systematic review of FDG-PET in breast cancer. Med Oncol 2010;27:114-29.
138. Samson D, Redding FC, Aronson N. FDG positron emission tomography for evaluating breast cancer. Chicago, IL: Blue Cross and Blue Shield Association, 2001.
139. Olson JA, Jr, McCall LM, Beitsch P, Whitworth PW, Reintgen DS, Blumencranz PW, et al. Impact of immediate versus delayed axillary node dissection on surgical outcomes in breast cancer patients with positive sentinel nodes: results from American College of Surgeons Oncology Group Trials Z0010 and Z0011. J Clin Oncol 2008;26(21):3530-5.
140. Bland KI. Re: axillary staging using positron emission tomography in breast cancer patients qualifying for sentinel lymph node biopsy. Breast J 2004;10(2):83-4.
141. Guller U, Nitzsche E, Moch H, Zuber M. Is positron emission tomography an accurate noninvasive alternative to sentinel lymph node biopsy in breast cancer patients? J Natl Cancer Inst 2003;95(14):1040-3.
142. Wahl RS. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging of breast cancer with PET study group. Womens Oncol Rev 2004;4(2):161-2.
143. Bahri S, Chen JH, Yu HJ, Kuzucan A, Nalcioglu O, Su MY. Can dynamic contrast-enhanced MRI (DCE-MRI) predict tumor recurrence and lymph node status in patients with breast cancer? Ann Oncol 2008;19(4):822-4.
144. Hsiang DJ, Yamamoto M, Mehta RS, Su MY, Baick CH, Lane KT, et al. Predicting nodal status using dynamic contrast-enhanced magnetic resonance imaging in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy with and without sequential trastuzumab. Arch Surg 2007;142(9):855-61.
145. Zytoon AA. Clinical relevance of the standardized uptake value (Suv) in staging breast cancer with FDG-PET/CT. Dokkyo J Med Sci 2007;34(3):193-204.
146. Adler LP, Crowe JP, al-Kaisi NK, Sunshine JL. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-d-glucose PET. Radiology 1993;187(3):743-50.
147. Bassa P, Kim EE, Inoue T, Wong FC, Korkmaz M, Yang DJ, et al. Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer. J Nucl Med 1996;37(6):931-8.
148. Beer AJ, Niemeyer M, Carlsen J, Sarbia M, Nahrig J, Watzlowik P, et al. Patterns of alphavbeta3 expression in primary and metastatic human breast cancer as shown by 18F-Galacto-RGD PET. J Nucl Med 2008;49(2):255-9.
149. Bombardieri E, Crippa F, Maffioli L, Chiti A, Castellani MR, Greco M, et al. Axillary lymph node metastases detection with nuclear medicine approaches in patients with newly diagnosed breast cancer: can positron emission tomography (PET) with 18F-FDG be considered as the best method? Int J Oncol 1996;8(4):693-9.
150. Burcombe RJ, Makris A, Pittam M, Lowe J, Emmott J, Wong WL. Evaluation of good clinical response to neoadjuvant chemotherapy in primary breast cancer using [18F]-fluorodeoxyglucose positron emission tomography. Eur J Cancer 2002;38(3):375-9.
151. Crowe JP, Jr, Adler LP, Shenk RR, Sunshine J. Positron emission tomography and breast masses: comparison with clinical, mammographic, and pathological findings. Ann Surg Oncol 1994;1(2):132-40.
152. Danforth DN, Aloj L, Carrasquillo JA, Bacharach SL, Chow C, Zujewski J, et al. The role of F-18-FDG-PET in the local/regional evaluation of women with breast cancer. Breast Cancer Res Treat 2002;75(2):135-46.
153. Harisinghani MG, Saksena MA, Hahn PF, King B, Kim J, Torabi MT, et al. Ferumoxtran-10- enhanced MR lymphangiography: does contrast-enhanced imaging alone suffice for accurate lymph node characterization? AJR Am J Roentgenol 2006;186(1):144-8.
154. Harisinghani MG, Weissleder R. Sensitive, noninvasive detection of lymph node metastases. PLoS Med 2004;1(3):202-9.
155. Hoh CK, Hawkins RA, Glaspy JA, Dahlbom M, Tse NY, Hoffman EJ, et al. Cancer-detection with whole-body Pet using 2-[F-18]Fluoro-2-Deoxy-d-Glucose. J Comput Assist Tomogr 1993;17(4):582-9.
156. Kelemen PR, Lowe V, Phillips N. Positron emission tomography and sentinel lymph node dissection in breast cancer. Clin Breast Cancer 2002;3(1):73-77.
157. Luciani A, Pigneur F, Ghozali F, Dao TH, Cunin P, Meyblum E, et al. Ex vivo MRI of axillary lymph nodes in breast cancer. Eur J Radiol 2009;69(1):59-66.
158. Noh DY, Yun IJ, Kang HS, Kim YC, Kim JS, Chung JK, et al. Detection of cancer in augmented breasts by positron emission tomography. Eur J Surg 1999;165(9):847-51.
159. Palmedo H, Bender H, Grunwald F, Mallmann P, Zamora P, Krebs D, et al. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and technetium-99m methoxyisobutylisonitrile scintimammography in the detection of breast tumours. Eur J Nucl Med 1997;24(9):1138-45.
160. Scheidhauer K, Scharl A, Pietrzyk U, Wagner R, Gohring UJ, Schomacker K, et al. Qualitative [18F]FDG positron emission tomography in primary breast cancer: clinical relevance and practicability. Eur J Nucl Med 1996;23(6):618-23.
161. Smyczek-Gargya B, Fersis N, Dittmann H, Vogel U, Reischl G, Machulla HJ, et al. PET with [18F]fluorothymidine for imaging of primary breast cancer: a pilot study. Eur J Nucl Med Mol Imaging 2004;31(5):720-4.
162. Sun X-CL. Comparative analysis of multi-slice spiral CT and positron emission tomography-CT in evaluation of axillary lymph nodes in breast cancer patients. Zhonghua Fang She Xian Yi Xue Za Zhi 2008;42(1):68-72.
163. Tse NY, Hoh CK, Hawkins RA, Zinner MJ, Dahlbom M, Choi Y, et al. The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease. Ann Surg 1992;216(1):27-34.
164. Vansant J, Balfore J, Monticciolo D, Votaw D, Carlson G, Garcia E, et al. (F-18)-FDG PET qualitative and quantitative assessment of breast cancer. J Nucl Med 1996;37(Suppl. 5):254P, abstract 1137.
165. Yang J-HN. Comparison of intraoperative frozen section analysis of sentinel node with preoperative positron emission tomography in the diagnosis of axillary lymph node status in breast cancer patients. Jpn J Clin Oncol 2001;31(1):1-6.
166. Black D, Specht M, Lee JM, Dominguez F, Gadd M, Hughes K, et al. Detecting occult malignancy in prophylactic mastectomy: preoperative MRI versus sentinel lymph node biopsy. Ann Surg Oncol 2007;14(9):2477-84.
167. Bollet MA, Thibault F, Bouillon K, Meunier M, Sigal-Zafrani B, Savignoni A, et al. Role of dynamic magnetic resonance imaging in the evaluation of tumor response to preoperative concurrent radiochemotherapy for large breast cancers: a prospective phase II study. Int J Radiat Oncol Biol Phys 2007;69(1):13-18.
168. Dose J, Bleckmann C, Bachmann S, Bohuslavizki KH, Berger J, Jenicke L, et al. Comparison of fluorodeoxyglucose positron emission tomography and "conventional diagnostic procedures" for the detection of distant metastases in breast cancer patients. Nucl Med Commun 2002;23(9):857-64.
169. Gil-Rendo A, Martinez-Regueira F, Zornoza G, Garcia-Velloso MJ, Beorlegui C, Rodriguez-Spiteri N, et al. Association between [18F]fluorodeoxyglucose uptake and prognostic parameters in breast cancer. Br J Surg 2009;96(2):166-70.
170. Kim S-JK. Predictive value of [18F]FDG PET for pathological response of breast cancer to neo-adjuvant chemotherapy. Ann Oncol 2004;15(9):1352-7.
171. Kubota K, Ogawa Y, Nishioka A, Murata Y, Itoh S, Hamada N, et al. Radiological imaging features of invasive micropapillary carcinoma of the breast and axillary lymph nodes. Oncol Rep 2008;20(5):1143-7.
172. Kumar R, Chauhan A, Zhuang HM, Chandra P, Schnall M, Alavi A. Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer. Breast Cancer Res Treat 2006;98(3):267-74.
173. Perman WH, Heiberg EV, Herrmann VM. Half-Fourier, three-dimensional technique for dynamic contrast-enhanced MR imaging of both breasts and axillae: initial characterization of breast lesions. Radiology 1996;200(1):263-9.
174. Alberini JL, Lerebours F, Wartski M, Fourme E, Le SE, Gontier E, et al. 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDGPET/ CT) imaging in the staging and prognosis of inflammatory breast cancer. Cancer 2009;115(21):5038-47.
175. Bathen TF, Jensen LR, Sitter B, Fjosne HE, Halgunset J, Axelson DE, et al. MR-determined metabolic phenotype of breast cancer in prediction of lymphatic spread, grade, and hormone status. Breast Cancer Res Treat 2007;104(2):181-9.
176. Bleckmann C, Dose J, Bohuslavizki KH, Buchert R, Klutmann S, Mester J, et al. Effect of attenuation correction on lesion detectability in FDG PET of breast cancer. J Nucl Med 1999;40(12):2021-4.
177. Buchmann I, Riedmuller K, Hoffner S, Mack U, Aulmann S, Haberkorn U. Comparison of 99mtechnetium-pertechnetate and 123iodide SPECT with FDG-PET in patients suspicious for breast cancer. Cancer Biother Radiopharm 2007;22(6):779-89.
178. Carkaci S, Macapinlac HA, Cristofanilli M, Mawlawi O, Rohren E, Gonzalez Angulo AM, et al. Retrospective study of 18F-FDG PET/CT in the diagnosis of inflammatory breast cancer: preliminary data. J Nucl Med 2009;50(2):231-8.
179. Chen JH, Baek HM, Nalcioglu O, Su MY. Estrogen receptor and breast MR imaging features: a correlation study. J Magn Reson Imaging 2008;27(4):825-33.
180. Chung A, Liou D, Karlan S, Waxman A, Fujimoto K, Hagiike M, et al. Preoperative FDGPET for axillary metastases in patients with breast cancer. Arch Surg 2006;141(8):783-8.
181. Dizendorf EV, Baumert BG, von Schulthess GK, Lutolf UM, Steinert HC. Impact of wholebody 18F-FDG PET on staging and managing patients for radiation therapy. J Nucl Med 2003;44(1):24-9.
182. Groheux D, Moretti JL, Baillet G, Espie M, Giacchetti S, Hindie E, et al. Effect of (18)F-FDG PET/CT imaging in patients with clinical Stage II and III breast cancer. Int J Radiat Oncol Biol Phys 2008;71(3):695-704.
183. Heusner TA, Kuemmel S, Umutlu L, Koeninger A, Freudenberg LS, Hauth EA, et al. Breast cancer staging in a single session: whole-body PET/CT mammography. J Nucl Med 2008;49(8):1215-22.
184. Matsushima S, Sasaki F, Yamaura H, Iwata H, Ohsaki H, Era S, et al. Equivalent crossrelaxation rate imaging for sentinel lymph node biopsy in breast carcinoma. Magn Reson Med 2005;54(5):1300-4.
185. Matsushima S, Nishiofuku H, Iwata H, Era S, Inaba Y, Kinosada Y. Equivalent crossrelaxation rate imaging of axillary lymph nodes in breast cancer. J Magn Reson Imaging 2008;27(6):1278-83.
186. Mavi A, Cermik TF, Urhan M, Zhuang H, Alavi A. Dual time point imaging method may increase the sensitivity and the specificity of FDG PET for detecting axillary metastasis from primary breast cancer. Eur J Nucl Med Mol Imaging 2006;33:S167.
187. Mortellaro VE, Marshall J, Singer L, Hochwald SN, Chang M, Copeland EM, et al. Magnetic resonance imaging for axillary staging in patients with breast cancer. J Magn Reson Imaging 2009;30(2):309-12.
188. Mussurakis S, Buckley DL, Horsman A. Dynamic MR imaging of invasive breast cancer: correlation with tumour grade and other histological factors. Br J Radiol 1997;70(833):446-51.
189. Nieweg OE, Kim EE, Wong WH, Broussard WF, Singletary SE, Hortobagyi GN, et al. Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer. Cancer 1993;71(12):3920-5.
190. Rotaru N, Luciani A, Rotaru N, Luciani A. Magnetic resonance imaging of the breast: potential for lesion characterization. J BUON 2004;9(1):77-82.
191. Schirrmeister H, Kuhn T, Guhlmann A, Santjohanser C, Horster T, Nussle K, et al. Fluorine-18 2-deoxy-2-fluoro-d-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. Eur J Nucl Med 2001;28(3):351-8.
192. Schirrmeister HH, Kuehn T, Buck AC, Santjohanser C, Reske SN. FDG-PET in preoperative assessment of newly diagnosed breast cancer. Breast Cancer Res Treat 2000;64(1):118, abstract 510.
193. Song B, Kim M, Lee J, Seo Y, Park W, Oh S, et al. Evaluation of PET-CT for axillary lymph node staging in patients with early stage breast cancer. EJC Supplements 2006;4(2):65, abstract 70.
194. Stets C, Brandt S, Wallis F, Buchmann J, Gilbert FJ, Heywang-Kobrunner SH. Axillary lymph node metastases: a statistical analysis of various parameters in MRI with USPIO. J Magn Reson Imaging 2002;16(1):60-8.
195. Torrenga HL. Re: Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-Dglucose- positron emission tomography: clinical evaluation and alternative management. J Natl Cancer Inst 2001;93(21):1659-61.
196. Ueda S, Tsuda H, Asakawa H, Shigekawa T, Fukatsu K, Kondo N, et al. Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer. Jpn J Clin Oncol 2008;38(4):250-8.
197. Yang SK, Cho N, Moon WK. The role of PET/CT for evaluating breast cancer. Korean J Radiol 2007;8(5):429-37.
198. Bock E, Bock C, Belli P, Campioni P, Manfredi R, Pastore G. [Role of diagnostic imaging of the breast in patients treated with postsurgical radiotherapy or presurgical radiotherapy or chemotherapy] [Italian]. Radiologia Medica 1998;95(1-2):38-43.
199. Chen SH, Ma QH, Li ZJ, Hu CW, Chen Sh, Ma Qh, et al. [Diagnosis of breast diseases by mammography in combination with MRI] [Chinese]. Zhongguo Yiliao Qixie Zazhi 2007;31(3):216-18.
200. Dose-Schwarz J, Mahner S, Schirrmacher S, Jenicke L, Muller V, Habermann CR, et al. [Detection of metastases in breast cancer patients: comparison of FDG PET with chest X-ray, bone scintigraphy and ultrasound of the abdomen] [German]. Nuclear-Medizin 2008;47(3):97-103.
201. Enya M, Goto H, Nandate Y, Kiryu T, Kanematsu M, Hoshi H. [Usefulness of dynamic MR mammography for diagnosis of axillary lymph node status in breast cancer patient]. [Japanese]. Nippon Igaku Hoshasen Gakkai Zasshi 2000;60(13):764-70.
202. Koga S, Nakano S, Honma Y, Ogasawara N. [FDG-PET (positron emission tomography) in the detection of primary breast cancer and lymph node involvement]. [Japanese]. Nippon Rinsho 2007;65(Suppl. 6):379-84.
203. Nakayama S, Kakizaki D, Kaise H, Kusama M, Ishikawa A, Amino M, et al. [Threedimentional volumetric interpolated breath-hold magnetic resonance imaging for the diagnosis of breast tumors] [Japanese]. Nippon Rinsho 2004;62(4):790-8.
204. Romer W, Avril N, Schwaiger M. [Possible uses of positron emission tomography in breast carcinoma]. Acta Medica Austriaca 1997;24(2):60-2.
205. Tiutin L, Fadeev N, Ryzhkova D, Kostenikiv N, Arzumanov A, Savello V, et al. [Clinical experience with positron emission tomography with 2-fluorine, 18F-2-deoxy-d-glucose used for the diagnosis of malignant breast neoplasms]. [Russian]. Vestn Rentgenol Radio 2001;6:14-18.
206. Zhao TT, Li JG, Li YM. [Performance of 18F-FDG PET/CT in the detection of primary breast cancer and staging of the regional lymph nodes] [Chinese]. Chung-Hua Chung Liu Tsa Chih 2007;29(3):206-9.
207. al-Yasi AR, Carroll MJ, Ellison D, Granowska M, Mather SJ, Wells CA, et al. Axillary node status in breast cancer patients prior to surgery by imaging with Tc-99m humanised anti- PEM monoclonal antibody, hHMFG1. Br J Cancer 2002;86(6):870-8.
208. Altinyollar H, Dingil G, Berberoglu U. Detection of infraclavicular lymph node metastases using ultrasonography in breast cancer. J Surg Oncol 2005;92(4):299-303.
209. Altomare V, Guerriero G, Carino R, Battista C, Primavera A, Altomare A, et al. Axillary lymph node echo-guided fine-needle aspiration cytology enables breast cancer patients to avoid a sentinel lymph node biopsy. Preliminary experience and a review of the literature. Surg Today 2007;37(9):735-9.
210. Holle LH, Trampert L, Lung-Kurt S, Villena-Heinsen CE, Puschel W, Schmidt S, et al. Investigations of breast tumors with fluorine-18-fluorodeoxyglucose and SPECT. J Nucl Med 1996;37(4):615-22.
211. 99mTc-sestamibi scintimammography for assessing axillary lymph node status in breast cancer patients. A prospective study. Eur J Surg Oncol 2006;32(9):933-6.
212. Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Drucker MJ, Livingston RB. Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [technetium 99m]-sestamibi scintimammography. Cancer 1999;85(11):2410-23.
213. Mansi L, Rambaldi PF, Procaccini E, DiGregorio F, Laprovitera A, Pecori B, et al. Scintimammography with technetium-99m tetrofosmin in the diagnosis of breast cancer and lymph node metastases. Eur J Nucl Med 1996;23(8):932-9.
214. Myslivecek M, Koranda P, Kaminek M, Husak V, Hartlova M, Duskova M, et al. Technetium- 99m-MIBI scintimammography by planar and SPECT imaging in the diagnosis of breast carcinoma and axillary lymph node involvement. Nucl Med Rev 2004;7(2):151-5.
215. Paredes P, Vidal-Sicart S, Zanon G, Pahisa J, Fernandez PL, Velasco M, et al. Clinical relevance of sentinel lymph nodes in the internal mammary chain in breast cancer patients. Eur J Nucl Med Mol Imaging 2005;32(11):1283-7.
216. Schillaci O, Scopinaro F, Danieli R, Tavolaro R, Cannas P, Picardi V, et al. Technetium-99m sestamibi imaging in the detection of axillary lymph node involvement in patients with breast cancer. Anticancer Res 1997;17(3B):1607-10.
217. Shien T, kashi-Tanaka S, Yoshida M, Hojo T, Iwamoto E, Miyakawa K, et al. Evaluation of axillary status in patients with breast cancer using thin-section CT. Int J Clin Oncol 2008;13(4):314-19.
218. Spanu A, Chessa F, Sanna D, Cottu P, Manca A, Nuvoli S, et al. Breast cancer axillary lymph node metastasis detection by a high-resolution dedicated breast camera: a comparative study with SPECT and pinhole SPECT. Cancer Biother Radiopharm 2007;22(6):799-811.
219. Spanu A, Dettori G, Chessa F, Porcu A, Cottu P, Solinas P, et al. Tc-99m-tetrofosmin pinhole- SPECT (P-SPECT) and radioguided sentinel node (SN) biopsy and in breast cancer axillary lymph node staging. Cancer Biother Radiopharm 2001;16(6):501-13.
220. Spanu A, Dettori G, Chiaramida P, Cottu P, Falchi A, Porcu A, et al. The role of Tc-99m- Tetrofosmin Pinhole-SPECT in breast cancer axillary lymph node staging. Cancer Biother Radiopharm 2000;15(1):81-91.
221. Spanu A, Tanda F, Dettori G, Manca A, Chessa F, Porcu A, et al. The role of Tc-99mtetrofosmin pinhole-SPECT in breast cancer non palpable axillary lymph node metastases detection. Q J Nucl Med 2003;47(2):116-28.
222. Sperber FW. Preoperative clinical, mammographic and sonographic assessment of neoadjuvant chemotherapy response in breast cancer. Isr Med Assoc J 2006;8(5):342-6.
223. Taillefer R, Robidoux A, Turpin S, Lambert R, Cantin J, Leveille J. Metastatic axillary lymph node technetium-99m-MIBI imaging in primary breast cancer. J Nucl Med 1998;39(3):459-64.
224. Taillefer R, Robidoux A, Lambert R, Turpin S, Laperriere J. Technetium-99M-sestamibi prone scintimammography to detect primary breast-cancer and axillary lymph-node involvement. J Nucl Med 1995;36(10):1758-65.
225. Dose J, Avril N, Graeff H, Jaenicke F. Positron emission tomography for diagnosis of breast tumors. Onkologie 1997;20(3):190-5.
226. Prati R, Minami CA, Gornbein JA, Debruhl N, Chung D, Chang HR, et al. Accuracy of clinical evaluation of locally advanced breast cancer in patients receiving neoadjuvant chemotherapy. Cancer 2009;115(6):1194-202.
227. Smith IC, Welch AE, Hutcheon AW, Miller ID, Payne S, Chilcott F, et al. Positron emission tomography using [F-18]-fluorodeoxy-d-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 2000;18(8):1676-88.
228. Bradley AJ, Carrington BM, Hammond CL, Swindell R, Magee B. Accuracy of axillary MR imaging in treated breast cancer for distinguishing between recurrent tumour and treatment effects: does intravenous Gd-DTPA enhancement help in cases of diagnostic dilemma? Clin Radiol 2000;55(12):921-8.
229. Lin W-YT. Fluorine-18 FDG-PET in detecting local recurrence and distant metastases in breast cancer - Taiwanese experiences. Cancer Invest 2002;20(5-6):725-9.
230. Mustafa S, Marshall C, Griffiths PA, Chuthapisith S, Wheatley DC, Eremin JM, et al. 18FFDG dual-headed gamma camera PET in detection of axillary nodal disease in patients with large or locally advanced breast cancer: possible alternative staging of axilla. Oncol Rep 2007;18(6):1545-9.
231. Ohta M, Tokuda Y, Saitoh Y, Suzuki Y, Okumura A, Kubota M, et al. Comparative efficacy of positron emission tomography and ultrasonography in preoperative evaluation of axillary lymph node metastases in breast cancer. Breast Cancer 2000;7(1):99-103.
232. Rostom AY, Powe J, Kandil A, Ezzat A, Bakheet S, el-Khwsky F, et al. Positron emission tomography in breast cancer: a clinicopathological correlation of results. Br J Radiol 1999;72(863):1064-8.